NasdaqGM:NRIXBiotechs
Nurix Therapeutics (NRIX) Is Down 7.4% After Pivotal Bexobrutideg Update and Wider 2025 Loss
In late January 2026, Nurix Therapeutics reported full-year 2025 revenue of US$83.98 million, up from US$54.55 million, alongside a wider net loss of US$264.46 million and an Employee Stock Ownership Plan-related shelf registration for up to 5,090,373 common shares worth about US$98.80 million.
The results came as Nurix advanced its lead BTK degrader bexobrutideg into pivotal DAYBREAK development with Orphan Drug and Fast Track status, backed by partnerships with Gilead, Sanofi, and Pfizer...